Urolog. pro Praxi, 2008; 9(1): 24-27

The cost of hormonal therapy for prostate cancer - Pharmacoeconomic aspects of treatment indications

Michaela Matoušková, Miroslav Hanuš
Urocentrum Praha, s.r.o

Hormonal therapy for prostate cancer (CaP) is among the primary therapeutic modalities. Since indication principles have been well established, the only issues which remain controversial are the initiation of therapy and the type of therapy, i. e., early versus delayed and continuous versus intermittent. To date, no modality has been shown to have superior features supported by EBM (evidence based medicine). In addition to these medical drawbacks, one cannot ignore the high cost of the therapy resulting from both the price of medications and their long-term use. This is an issue addressed even in economically strong countries.

Keywords: prostate cancer, hormonal therapy, economy

Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matoušková M, Hanuš M. The cost of hormonal therapy for prostate cancer - Pharmacoeconomic aspects of treatment indications. Urol. praxi. 2008;9(1):24-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bayoumi AH, Brown AD, Gerber AM. Cost effectiveness of androgen suppresion therapies in advances prostate cancer. J Nat Can Int. 2000; 92(21). Go to original source... Go to PubMed...
    2. Calais da Silva F, Calais de Silva FM, Bono A et al. Phase III intermitent MAB vs. continous MAB. J Clin Oncol 2006; 24(Suppl 18): 4513. Go to original source...
    3. Dušek P, Kawaciuk I, Jarolím L a kol. Intermitentní androgenní suprese u karcinomu prostaty - desetileté zkušenosti. In: Abrahámová J. Vybrané otázky z okologie. Praha: Galén, 2007: 77-79.
    4. Hillner BE, Roberts JD. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer. J Nat Can Int. 2000; 92(21). Go to original source... Go to PubMed...
    5. Matoušková M, Hanuš M. Intermitentní androgenní suprese (IAS) v léčbě karcinomu prostaty. Czech Urol 2003; 7: 11-15.
    6. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 2007; 99(Suppl 1): 19-22. Go to original source... Go to PubMed...
    7. Vyhláška o úhradách léčiv a potravin pro zvláštní účely. Sbírka zákonů č. 63/2007 ze dne 22. 3. 2007, Praha: Tiskárna Ministerstva vnitra: 646-836.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.